AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $38,000.00 income · posted Oct 15, 2025

Lobbying activity 1

Health Issues

- ultrarare disease - newborn screening - pediatric priority review voucher

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.